Intercell AG

euro adhoc: Intercell AG
quarterly or semiannual financial statement / Intercell AG announces Q3 results and presents business update: All development programs on track - Profitability expected for full year 2007 - Very strong financial position - ...

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

quaterly report


Vienna (Austria), November 19, 2007 - Today, vaccine company Intercell AG (VSE: ICLL) announced its financial results for the third quarter 2007, and presented an update on the Company´s development programs.

All development programs fully on track

Japanese Encephalitis:

» Significant progress for leading prophylactic vaccine program on track for    market approvals - Finalization of EMEA-MAA and US-BLA filing planned for    December 2007

» Results of Phase II for the vaccine in children expected in early 2008

Hospital acquired infections:

» S. aureus vaccine - Start of clinical Phase II trial (with Merck & Co.,    Inc.) expected within the next weeks

» Pseudomonas vaccine - preparations for start of clinical Phase II/III    trials in 2008 on track

Hepatitis C:

» Statistically significant viral load reduction and good safety profile for    therapeutic vaccine in interim analysis - full study data expected for Q1    2008

» Further clinical program under co-development arrangement with Novartis    likely to include IC31®

IC31® & AIP®:

» IC31® - Influenza vaccine: All individuals within Phase I study vaccinated    - results expected for early 2008

» IC31® - Tuberculosis vaccine: Two further clinical trials with the Danish    Statens Serum Institut (SSI) expected to start this year

» Pneumococcus vaccine: Preparations for start of Phase I study in 2008 for    novel protein-based vaccine on track

Novartis alliance:

» Transaction closed as announced in July - Total upfront contribution of    EUR 270 m - Significant further milestones expected - 4.8 m shares issued    to Novartis at a price of EUR 31.25 per share in September

» Full implementation for improved Influenza vaccine and co-development in    Hepatitis C started in Q4 2007

Strong financial position - Profitability expected for full year 2007

» EUR 6.5 m net loss for Q3 2007 compared to EUR 9.5 m in Q3 2006. This means    a decrease of 31.2 percent

» Increase of aggregate revenues - EUR 7.4 m in Q3 2007 compared to EUR 0.7 m    in Q3 2006

» EUR 9.8 m R&D expenses in Q3 2007 - up 17.0 percent compared to Q3 2006    following progress of development programs

» Strong cash position with EUR 218.6 m in liquid funds at September 30,    2007.Given already committed further payments, cash position at the end of    2007 expected to be approx. EUR 300 m

» Full year 2007 expected to be profitable based on already confirmed   licensing income. Growth in profitability expected for 2008

Management Board:

» Management Board, with Gerd Zettlmeissl as Chief Executive Officer, Werner    Lanthaler as Chief Financial Officer, and Alexander von Gabain as Chief    Scientific Officer, appointed for a further three-year term. Thomas    Lingelbach appointed as a new member of the Management Board as Chief    Operating Officer

@@start.t2@@end of announcement                                                 euro adhoc 19.11.2007 07:24:55

ots Originaltext: Intercell AG
Im Internet recherchierbar:

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: